ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.40 | 1.33 | -0.17 |
| FCF Yield | 4.41% | 10.12% | -7.29% | -3.50% |
| EV / EBITDA | 24.51 | 9.92 | 35.64 | 246.31 |
| Quality | ||||
| ROIC | 0.04% | 5.84% | -4.08% | -4.42% |
| Gross Margin | 59.27% | 62.71% | 56.13% | 53.45% |
| Cash Conversion Ratio | -3.46 | 6.33 | 0.65 | -0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.76% | 31.08% | 14.92% | 1.52% |
| Free Cash Flow Growth | -53.15% | 310.77% | -134.58% | 61.71% |
| Safety | ||||
| Net Debt / EBITDA | 7.59 | 0.61 | 9.52 | 60.04 |
| Interest Coverage | 0.03 | 1.74 | -1.26 | -3.34 |
| Efficiency | ||||
| Inventory Turnover | 1.83 | 1.63 | 1.32 | 1.23 |
| Cash Conversion Cycle | 264.66 | 271.36 | 390.87 | 430.10 |